Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)

Next Previous
Trial Profile

A phase IIb clinical study of PDS-0101 in combination with other immune-modulating agents in HPV16-positive and HIV-positive subjects with high-grade anal intraepithelial neoplasia (anal pre-cancer)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PDS 0101 (Primary)
  • Indications Anal intraepithelial neoplasia
  • Focus Therapeutic Use

    • Most Recent Events

    • 19 Sep 2019 According to a PDS Biotechnology Corporation media release, this trial is expected to start in the first quarter of 2020.
    • 29 May 2019 According to a PDS Biotechnology Corporation media release, Dr. Jeffrey Schlom, Chief, LTIB, and Dr. James Gulley, Chief, GMB, at NCI will serve as principal investigators for the NCI, while Dr. Frank Bedu-Addo and Dr. Lauren Wood, PDS Chief Medical Officer, will serve as PDS investigators.
    • 12 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top